National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Nintedanib (Ofev®) HTA ID: 20034

Nintedanib is indicated for the treatment of other progressive, chronic fibrosing interstitial lung diseases (PF-ILD) in adults.

 

NCPE Assessment Process Complete
Rapid review commissioned 17/07/2020
Rapid review completed 28/08/2020
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of nintedanib compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by the HSE 01/09/2020
Pre submission consultation with Applicant 05/10/2020
Full submission received from Applicant 10/11/2020
Preliminary review sent to Applicant 16/03/2021
NCPE assessment re-commenced 15/04/2021
Follow-up preliminary review sent to Applicant 21/04/2021
NCPE assessment re-commenced 30/04/2021
Factual accuracy check sent to Applicant 28/05/2021
NCPE assessment re-commenced 04/06/2021
NCPE assessment completed 24/06/2021
NCPE assessment outcome The NCPE recommends that nintedanib (Ofev®) not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*.

 

Technical Summary

Plain English Summary

 

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.